Product Description
Avadomide (CC_122) is a novel cereblon_binding agent that exhibits antilymphoma and immune_modulation activities with a biological profile distinct from similar agents, such as lenalidomide.Ê (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780008/)
Mechanisms of Action: CRBN Modulator,IKZF1 Inducer,IKZF3 Inducer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Italy, Japan, Netherlands, Spain, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Diffuse Large B-Cell Lymphoma|Glioblastoma|Lymphoma, Non-Hodgkin|Multiple Myeloma|Primary Central Nervous System Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CA092-1000 | P1 |
Active, not recruiting |
Lymphoma, Non-Hodgkin |
2026-02-25 |
28% |
CC-122-ST-001 | P1 |
Completed |
Glioblastoma|Multiple Myeloma|Primary Central Nervous System Lymphoma|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin |
2023-11-21 |